Compare FARM & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FARM | NRSN |
|---|---|---|
| Founded | 1912 | 2017 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.8M | 26.4M |
| IPO Year | N/A | 2021 |
| Metric | FARM | NRSN |
|---|---|---|
| Price | $1.48 | $0.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.75 | ★ $14.00 |
| AVG Volume (30 Days) | 67.7K | ★ 356.5K |
| Earning Date | 02-05-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $338,816,000.00 | N/A |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $3.31 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.34 | $0.76 |
| 52 Week High | $3.29 | $2.60 |
| Indicator | FARM | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 42.12 | 35.99 |
| Support Level | $1.44 | $0.76 |
| Resistance Level | $1.58 | $0.91 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 18.75 | 11.65 |
Farmer Bros Co is engaged in manufacturing, wholesaling, and distributing coffee, tea, and culinary products to food-service establishments and retailers in the United States. The company's customers include restaurants, hotels, offices, casinos, convenience stores, healthcare facilities, and other food-service providers. The company's product categories include roast and ground coffee, frozen liquid coffee, flavored and unflavored iced and hot teas, culinary products, spices, and other beverages, such as cappuccino, cocoa, granitas, and ready-to-drink iced coffee.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.